194 related articles for article (PubMed ID: 23862618)
1. Medicinal chemistry of quinolines as emerging anti-inflammatory agents: an overview.
Mukherjee S; Pal M
Curr Med Chem; 2013; 20(35):4386-410. PubMed ID: 23862618
[TBL] [Abstract][Full Text] [Related]
2. Quinolines: a new hope against inflammation.
Mukherjee S; Pal M
Drug Discov Today; 2013 Apr; 18(7-8):389-98. PubMed ID: 23159484
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic significance of quinolines: a patent review (2013-2015).
Hussaini SM
Expert Opin Ther Pat; 2016 Oct; 26(10):1201-21. PubMed ID: 27458877
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, Structural Characterization and Antinociceptive Activities of New Arylated Quinolines via Suzuki-Miyaura Cross Coupling Reaction.
Ullah MA; Adeel M; Tahir MN; Rauf A; Akram M; Hadda TB; Mabkhot YN; Muhammad N; Naseer F; Mubarak MS
Med Chem; 2017; 13(8):780-786. PubMed ID: 28676003
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R; Azizi E; Daraie B; Hedayati M; Dadrass OG
Bioorg Med Chem; 2009 Jul; 17(14):5312-7. PubMed ID: 19560931
[TBL] [Abstract][Full Text] [Related]
6. Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry.
Yadav P; Shah K
Bioorg Chem; 2021 Apr; 109():104639. PubMed ID: 33618829
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells.
Kwak SH; Shin S; Lee JH; Shim JK; Kim M; Lee SD; Lee A; Bae J; Park JH; Abdelrahman A; Müller CE; Cho SK; Kang SG; Bae MA; Yang JY; Ko H; Goddard WA; Kim YC
Eur J Med Chem; 2018 May; 151():462-481. PubMed ID: 29649742
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, molecular docking and anti-inflammatory screening of novel quinoline incorporated pyrazole derivatives using the Pfitzinger reaction II.
El-Feky SA; Abd El-Samii ZK; Osman NA; Lashine J; Kamel MA; Thabet HKh
Bioorg Chem; 2015 Feb; 58():104-16. PubMed ID: 25590381
[TBL] [Abstract][Full Text] [Related]
9. Glycoconjugates of Quinolines: Application in Medicinal Chemistry.
Oliveri V; Vecchio G
Mini Rev Med Chem; 2016 Sep; 16(15):1185-1194. PubMed ID: 27145851
[TBL] [Abstract][Full Text] [Related]
10. Quinoline-derivatives as privileged scaffolds for medicinal and pharmaceutical chemists: A comprehensive review.
Yadav V; Reang J; Sharma V; Majeed J; Sharma PC; Sharma K; Giri N; Kumar A; Tonk RK
Chem Biol Drug Des; 2022 Sep; 100(3):389-418. PubMed ID: 35712793
[TBL] [Abstract][Full Text] [Related]
11. Styrylquinolines Derivatives: SAR Study and Synthetic Approaches.
Saini M; Das R; Mehta DK; Chauhan S
Med Chem; 2022; 18(8):859-870. PubMed ID: 35156587
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Pyrazolo[4,3-
Tseng CH; Tung CW; Peng SI; Chen YL; Tzeng CC; Cheng CM
Molecules; 2018 Apr; 23(5):. PubMed ID: 29710774
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and anti-inflammatory evaluation of 4-anilinofuro[2,3-b]quinoline and 4-phenoxyfuro[2,3-b]quinoline derivatives. Part 3.
Chen YL; Chen IL; Lu CM; Tzeng CC; Tsao LT; Wang JP
Bioorg Med Chem; 2004 Jan; 12(2):387-92. PubMed ID: 14723957
[TBL] [Abstract][Full Text] [Related]
14. C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.
Kumar KS; Kiran Kumar S; Yogi Sreenivas B; Gorja DR; Kapavarapu R; Rambabu D; Rama Krishna G; Reddy CM; Basaveswara Rao MV; Parsa KV; Pal M
Bioorg Med Chem; 2012 Apr; 20(7):2199-207. PubMed ID: 22386978
[TBL] [Abstract][Full Text] [Related]
15. Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective.
Sharma S; Singh A; Sharma S; Sharma R; Singh J; Kinarivala N; Nepali K; Liou JP
Anticancer Agents Med Chem; 2021; 21(3):288-315. PubMed ID: 32900354
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-Substituted 3-Arylquinoline Derivatives as Potential Anti-Inflammatory Agents Through Inhibition of LPS-Induced Inflammatory Responses in Macrophages.
Yang CY; Hung YL; Tang KW; Wang SC; Tseng CH; Tzeng CC; Liu PL; Li CY; Chen YL
Molecules; 2019 Mar; 24(6):. PubMed ID: 30909606
[TBL] [Abstract][Full Text] [Related]
17. Friedlӓnder's synthesis of quinolines as a pivotal step in the development of bioactive heterocyclic derivatives in the current era of medicinal chemistry.
Rajendran S; Sivalingam K; Karnam Jayarampillai RP; Wang WL; Salas CO
Chem Biol Drug Des; 2022 Dec; 100(6):1042-1085. PubMed ID: 35322543
[TBL] [Abstract][Full Text] [Related]
18. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Indeno[1,2-c]quinoline Derivatives as Potent Dual Antituberculosis and Anti-Inflammatory Agents.
Tseng CH; Tung CW; Wu CH; Tzeng CC; Chen YH; Hwang TL; Chen YL
Molecules; 2017 Jun; 22(6):. PubMed ID: 28621733
[TBL] [Abstract][Full Text] [Related]
20. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
